ソラフェニブの世界市場レポート (2024年)

ソラフェニブの市場規模は、今後数年間で安定した成長が見込まれます。2028年にはCAGR4.2%で14億7,000万米ドルに成長します。予測期間中に予想される成長は、甲状腺がんの罹患率の上昇、がん症例の全体的な増加、慢性疾患の有病率の上昇、精密医療への注目の高まり、肝臓がんと腎臓がんの罹患率の上昇に起因しています。この期間に予想される主な動向には、早期診断・治療の進歩、代替療法の革新、肝細胞がん (HCC) 治療の進展、ドラッグデリバリーの技術革新、腎細胞がん治療の進展などがあります。

がん罹患率の上昇は、今後のソラフェニブ市場の成長を牽引すると予想されます。がんとは、異常細胞の制御不能な増殖と分裂を特徴とする疾患の総称であり、健康な組織に侵入して損傷を与える可能性があります。がんの有病率の増加は、高齢化、ライフスタイルの選択、環境暴露、診断技術の進歩など様々な要因に起因しており、その結果、より多くの症例が特定されています。マルチキナーゼ阻害剤であるソラフェニブは、腫瘍増殖や血管新生に関与する重要なシグナル伝達経路を標的とするため、がん治療に不可欠であり、進行した腎細胞がんや肝細胞がんの患者にとって効果的な治療選択肢となっています。例えば、米国の政府間機関である国立生物工学情報センター (National Center for Biotechnology Information) は、2023年1月に約195万8310人の新規がん患者と60万9820人のがん関連死亡者を報告しました。このように、がんの有病率の増加がソラフェニブ市場の拡大に拍車をかけています。

ソラフェニブ市場の主要企業は、手頃な価格のソラフェニブジェネリック錠剤など、がん治療における特定の要件を満たしながら有効性と患者のアドヒアランスを向上させる革新的な製品の創出に注力しています。手頃な価格のジェネリック医薬品は、先発医薬品と同じ治療効果を持ちながら、はるかに低価格です。これらの医薬品は、先発品と同等の臨床効果を発揮しながら、ヘルスケアコストの削減に貢献しています。例えば、2022年6月、インドの製薬メーカーであるDr. Reddy's Laboratoriesは、米国食品医薬品局 (USFDA) の承認を得て、様々ながんのジェネリック治療薬であるソラフェニブ錠を米国市場に投入しました。このジェネリック医薬品はバイエル社のネクサバールをベースとしたもので、肝臓がん、腎臓がん、甲状腺がんなど複数のがんの治療に使用されます。ソラフェニブの錠剤は200mg用量で、120錠入りのボトルで販売されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の市場規模と成長

• 世界のソラフェニブ市場の促進要因と抑制要因
  • 市場の促進要因
  • 市場の抑制要因
• 世界のソラフェニブの市場規模・成長率：実績値、2018～2023年
• 世界のソラフェニブの市場規模・成長率：予測値、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界のソラフェニブ市場：製品別、実績と予測, 2018-2023, 2023-2028F, 2033F
• 特許医薬品
• ジェネリック医薬品
• 世界のソラフェニブ市場：流通チャネル別、実績と予測, 2018-2023, 2023-2028F, 2033F
• 病院薬局
• ドラッグストアと小売薬局
• オンライン薬局
• 世界のソラフェニブ市場：用途別、実績と予測, 2018-2023, 2023-2028F, 2033F
• 腎臓がん
• 肝臓がん
• 甲状腺がん

第7章 地域別・国別の分析

• 世界のソラフェニブ市場：地域別、実績値・予測値、2018年～2023年、2023～2028年、2033年
• 世界のソラフェニブ市場：国別、実績値・予測値、2018年～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ソラフェニブ市場：競合情勢
• ソラフェニブ市場：企業プロファイル
  • Pfizer Inc.
  • Bayer AG
  • AstraZeneca PLC
  • Novartis AG
  • Bristol Myers Squibb

第31章 その他の大手企業と革新的企業

• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Amgen Inc.
• Cipla Limited
• Hikma Pharmaceuticals PLC
• Dr. Reddy's Laboratories Ltd.
• Exelixis Inc.
• Natco Pharma
• Beacon Pharmaceuticals Ltd.
• Hetero Healthcare Ltd.
• Aprazer Healthcare Private Limited
• Wellona Pharma
• Anant Pharmaceuticals Pvt. Ltd.
• Intelicure Lifescience

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Sorafenib is a medication primarily used in the treatment of certain types of cancer. It is classified as a targeted therapy drug, functioning by inhibiting specific enzymes and proteins that are involved in cancer cell growth and the formation of blood vessels in tumors.

The main product types of sorafenib include patented drugs and generic drugs. Patented drugs are medications protected by intellectual property rights, usually through a patent granted to the company or individual who discovered or developed the drug. Sorafenib is distributed through various channels, including hospital pharmacies, drug stores, retail pharmacies, and online pharmacies. It is used in the treatment of several conditions, including kidney cancer, liver cancer, and thyroid cancer.

The sorafenib market research report is one of a series of new reports from The Business Research Company that provides sorafenib market statistics, including sorafenib industry global market size, regional shares, competitors with a sorafenib market share, detailed sorafenib market segments, market trends, and opportunities, and any further data you may need to thrive in the sorafenib industry. This sorafenib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sorafenib market size has grown steadily in recent years. It will grow from $1.19 billion in 2023 to $1.24 billion in 2024 at a compound annual growth rate (CAGR) of 4.1%. The growth during the historical period can be attributed to favorable government policies and reimbursement programs, an increase in approvals for new drugs, rising apoptosis in cancer cells, a growing incidence of target cancers, and an increase in research studies focused on sorafenib.

The sorafenib market size is expected to see steady growth in the next few years. It will grow to $1.47 billion in 2028 at a compound annual growth rate (CAGR) of 4.2%. The anticipated growth during the forecast period can be attributed to the rising incidence of thyroid cancer, an overall increase in cancer cases, a growing prevalence of chronic diseases, a heightened focus on precision medicine, and a rising incidence of liver and renal cancers. Key trends expected during this period include advancements in early diagnosis and treatment, innovations in alternative therapies, developments in advanced hepatocellular carcinoma (HCC) treatments, technological innovations in drug delivery, and progress in advanced renal cell carcinoma therapies.

The rising incidence of cancer is anticipated to drive the growth of the sorafenib market in the future. Cancer refers to a collection of disorders characterized by the uncontrolled growth and division of abnormal cells, which can invade and damage healthy tissues. The increasing prevalence of cancer can be attributed to various factors, including an aging population, lifestyle choices, environmental exposures, and advancements in diagnostic technologies that result in more cases being identified. Sorafenib, a multi-kinase inhibitor, is essential in cancer treatment as it targets critical signaling pathways involved in tumor growth and angiogenesis, making it an effective therapeutic option for patients with advanced renal cell carcinoma and hepatocellular carcinoma. For example, in January 2023, the National Center for Biotechnology Information, a US-based intergovernmental organization, reported approximately 1,958,310 new cancer cases and 609,820 cancer-related deaths in 2023. Thus, the increasing prevalence of cancer is fueling the expansion of the sorafenib market.

Key players in the sorafenib market are concentrating on creating innovative products, such as affordable generic sorafenib tablets, to improve efficacy and patient adherence while meeting specific requirements in cancer treatment. Affordable generic medicines provide the same therapeutic benefits as their brand-name counterparts but at much lower prices. These medications help to lower healthcare costs while delivering equivalent clinical efficacy to their branded versions. For instance, in June 2022, Dr. Reddy's Laboratories, an Indian pharmaceutical manufacturer, introduced Sorafenib tablets, a generic treatment for various cancers, in the US market after receiving approval from the US Food and Drug Administration (USFDA). This generic product is based on Bayer's Nexavar and is used for treating multiple cancers, including liver, kidney, and thyroid cancers. The Sorafenib tablets are available in 200 mg doses and are sold in bottles containing 120 tablets.

In June 2024, Lotus Pharmaceuticals Co. Ltd., a Taiwan-based company focused on manufacturing and selling generic drugs, acquired Teva Pharmaceutical Industries Ltd. for an undisclosed amount. This acquisition allows Lotus Pharmaceuticals to broaden its product range and market presence by integrating Teva's extensive portfolio of pharmaceutical products and expertise. Teva Pharmaceutical Industries Ltd. is an Israel-based company that produces sorafenib tablets.

Major companies operating in the sorafenib market are Pfizer Inc., Bayer AG, AstraZeneca PLC, Novartis AG, Bristol Myers Squibb , Mylan N.V., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Amgen Inc., Cipla Limited, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories Ltd., Exelixis Inc., Natco Pharma, Beacon Pharmaceuticals Ltd., Hetero Healthcare Ltd., Aprazer Healthcare Private Limited, Wellona Pharma, Anant Pharmaceuticals Pvt. Ltd., Intelicure Lifescience

North America was the largest region in the sorafenib market in 2023. The regions covered in the sorafenib market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the sorafenib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sorafenib market consists of sales of nexavar, and sorafenib combination tablets. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sorafenib Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sorafenib market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sorafenib ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sorafenib market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Patented Drugs; Generic Drugs
• 2) By Distribution Channel: Hospital Pharmacies; Drug Store And Retail Pharmacies; Online Pharmacies
• 3) By Application: Kidney Cancer; Liver Cancer; Thyroid Cancer
• Companies Mentioned: Pfizer Inc.; Bayer AG; AstraZeneca PLC; Novartis AG; Bristol Myers Squibb
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Sorafenib Market Characteristics

3. Sorafenib Market Trends And Strategies

4. Sorafenib Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Sorafenib Market Size and Growth

• 5.1. Global Sorafenib Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Sorafenib Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Sorafenib Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Sorafenib Market Segmentation

• 6.1. Global Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Patented Drugs
• Generic Drugs
• 6.2. Global Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Drug Store And Retail Pharmacies
• Online Pharmacies
• 6.3. Global Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Kidney Cancer
• Liver Cancer
• Thyroid Cancer

7. Sorafenib Market Regional And Country Analysis

• 7.1. Global Sorafenib Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Sorafenib Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Sorafenib Market

• 8.1. Asia-Pacific Sorafenib Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Sorafenib Market

• 9.1. China Sorafenib Market Overview
• 9.2. China Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Sorafenib Market

• 10.1. India Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Sorafenib Market

• 11.1. Japan Sorafenib Market Overview
• 11.2. Japan Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Sorafenib Market

• 12.1. Australia Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Sorafenib Market

• 13.1. Indonesia Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Sorafenib Market

• 14.1. South Korea Sorafenib Market Overview
• 14.2. South Korea Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Sorafenib Market

• 15.1. Western Europe Sorafenib Market Overview
• 15.2. Western Europe Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Sorafenib Market

• 16.1. UK Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Sorafenib Market

• 17.1. Germany Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Sorafenib Market

• 18.1. France Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Sorafenib Market

• 19.1. Italy Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Sorafenib Market

• 20.1. Spain Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Sorafenib Market

• 21.1. Eastern Europe Sorafenib Market Overview
• 21.2. Eastern Europe Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Sorafenib Market

• 22.1. Russia Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Sorafenib Market

• 23.1. North America Sorafenib Market Overview
• 23.2. North America Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Sorafenib Market

• 24.1. USA Sorafenib Market Overview
• 24.2. USA Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Sorafenib Market

• 25.1. Canada Sorafenib Market Overview
• 25.2. Canada Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Sorafenib Market

• 26.1. South America Sorafenib Market Overview
• 26.2. South America Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Sorafenib Market

• 27.1. Brazil Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Sorafenib Market

• 28.1. Middle East Sorafenib Market Overview
• 28.2. Middle East Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Sorafenib Market

• 29.1. Africa Sorafenib Market Overview
• 29.2. Africa Sorafenib Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Sorafenib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Sorafenib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Sorafenib Market Competitive Landscape And Company Profiles

• 30.1. Sorafenib Market Competitive Landscape
• 30.2. Sorafenib Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Bayer AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. AstraZeneca PLC
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Novartis AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bristol Myers Squibb
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Sorafenib Market Other Major And Innovative Companies

• 31.1. Mylan N.V.
• 31.2. Teva Pharmaceutical Industries Ltd.
• 31.3. Astellas Pharma Inc.
• 31.4. Amgen Inc.
• 31.5. Cipla Limited
• 31.6. Hikma Pharmaceuticals PLC
• 31.7. Dr. Reddy's Laboratories Ltd.
• 31.8. Exelixis Inc.
• 31.9. Natco Pharma
• 31.10. Beacon Pharmaceuticals Ltd.
• 31.11. Hetero Healthcare Ltd.
• 31.12. Aprazer Healthcare Private Limited
• 31.13. Wellona Pharma
• 31.14. Anant Pharmaceuticals Pvt. Ltd.
• 31.15. Intelicure Lifescience

32. Global Sorafenib Market Competitive Benchmarking

33. Global Sorafenib Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Sorafenib Market

35. Sorafenib Market Future Outlook and Potential Analysis

• 35.1 Sorafenib Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Sorafenib Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Sorafenib Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer